TEVA’s price movements
Teva Pharmaceutical (TEVA) is a leading global pharmaceutical company with a market cap of $17.21 billion as of January 8. On the day, the company closed at $17.68 on the NYSE, up 0.06% from its previous closing price.
On January 2, Teva Pharmaceutical issued a press release announcing the settlement of an ongoing patent infringement litigation with Amgen (AMGN) related to the latter’s secondary hyperparathyroidism drug, Sensipar.
Based on its closing price on January 8, the company had reported returns of 14.66% in the last week, -12.73% in the last month, and -17.77% in the last quarter. Teva Pharmaceutical had also reported returns of -27.09% in the last half year, -8.01% in the last year, and 14.66% YTD (year-to-date).
Based on its closing price on January 8, the broader healthcare sector represented by the Health Care Select Sector SPDR ETF (XLV) had reported returns of 0.52% in the last week, -6.42% in the last month, and -7.77% in the last quarter. XLV had also reported returns of 0.37% in the last half year, 2.01% in the last year, and 0.52% YTD.
Analysts’ recommendations and target prices for Teva
The 12-month consensus analyst recommendation for Teva Pharmaceutical as of January 9 is a “hold.” The 12-month consensus target price for the company is $22.71, 28.45% higher than its closing price on January 8. The highest target price estimate for the company is $30, and the lowest target price estimate is $15.
Of the 23 analysts covering Teva Pharmaceutical on January 9, two analysts have rated the company as a “strong buy,” three have rated it as a “buy,” 15 have rated it as a “hold,” and three have rated it as a “sell.”
In the next article, we’ll discuss analysts’ recommendations for Mylan in greater detail.